产品说明书

5-Fluorouracil

Print
Chemical Structure| 51-21-8 同义名 : 5-氟脲嘧啶 ;5-FU;NSC 19893;Trade name: Adrucil and many others.;U-8953;Ro 2-9757;Fluorouracil
CAS号 : 51-21-8
货号 : A370752
分子式 : C4H3FN2O2
纯度 : 98%
分子量 : 130.08
MDL号 : MFCD00006018
存储条件:

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(384.39 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 10 mg/mL(76.88 mM),配合低频超声,并水浴加热至45℃助溶

动物实验配方:

IP 2% DMSO+water 2 mg/mL clear

PO 0.5% CMC-Na 60 mg/mL suspension

生物活性
描述 5-Fluorouracil (5-FU), or combined with other chemotherapeutic agents, is widely used in the treatment of a range of cancers, including colorectal and breast cancers, head and neck cancers, cancers of the aerodigestive tract[1]. 5-Fluorouracil can disrupt RNA synthesis through RNA mis-incorporation by its active metabolites, as well as block dTMP synthesis through inhibition of thymidylate synthase. After entering into cells, 5-Fluorouracil can be converted to its active metabolites, fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate[2]. FdUMP can inhibit the thymidylate synthase through binding to the nucleotide-binding site of thymidylate synthase, thus blocking the binding of normal substrate dUMP and inhibiting dTMP synthesis. And this will cause the disruption of DNA replication and repair[3]. FUTP can extensively incorporate into RNA and disrupt RNA processing and function[4]. Thus, 5-Fluorouracil showed cytotoxicity in various cells.
作用机制 The mechanism of cytotoxicity of 5-FU has been ascribed to the mis-incorporation of fluoronucleotides into RNA and DNA, as well as the inhibition of thymidylate synthase[4].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
HL-60 Growth Inhibition Assay 72 h  IC50=8.601 μg/mL 24095176
HT-29 Growth Inhibition Assay 72 h  IC50> 25 μg/mL 24095176
MCF-7 Growth Inhibition Assay 72 h  IC50=20 μg/mL 24095176
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

7.69mL

1.54mL

0.77mL

38.44mL

7.69mL

3.84mL

76.88mL

15.38mL

7.69mL

参考文献

[1]Longley DB, Harkin DP, et al. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8.

[2]Diasio RB, Harris BE, et al. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989 Apr;16(4):215-37.

[3]Santi DV, McHenry CS, et al. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry. 1974 Jan 29;13(3):471-81.

[4]Glazer RI, Lloyd LS, et al. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol. 1982 Mar;21(2):468-73.

[5]Cao Z, Zhang Z, et al. Antitumor and immunomodulatory effects of low-dose 5-FU on hepatoma 22 tumor-bearing mice. Oncol Lett. 2014 Apr;7(4):1260-1264. Epub 2014 Feb 6.

[6]Song MK, Park MY, et al. 5-Fluorouracil-induced changes of intestinal integrity biomarkers in BALB/c mice. J Cancer Prev. 2013 Dec;18(4):322-9.

[7]Li J, Chen Y, et al. Simultaneous determination of the novel anti-tumor candidate drug MDH-7 and 5-fluorouracil in rat plasma by LC-MS/MS: Application to pharmacokinetic interactions. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 15;1095:235-240.